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Clinical PerspectiveWhat Is New?The prognostic value of cardiovascular biomarkers (NT‐proBNP \[N‐terminal pro‐B‐type natriuretic peptide\], growth differentiation factor‐15, and troponin) for stroke, death, and major bleeding is not affected by left ventricular hypertrophy in patients with atrial fibrillation.What Are the Clinical Implications?Cardiac biomarkers are able to further identify patients with lower or higher risk both in the presence and in the absence of left ventricular hypertrophy by ECG.

Introduction {#jah33798-sec-0009}
============

Atrial fibrillation (AF), the most common sustained arrhythmia, substantially increases the risk of stroke and mortality.[1](#jah33798-bib-0001){ref-type="ref"}, [2](#jah33798-bib-0002){ref-type="ref"} Left ventricular hypertrophy (LVH) is a recognized risk factor for cardiovascular disease and mortality.[3](#jah33798-bib-0003){ref-type="ref"} Recently, LVH diagnosed by ECG was also confirmed to be a predictor in patients with AF for risk of stroke and death.[4](#jah33798-bib-0004){ref-type="ref"} Similarly, cardiac biomarkers are well‐known predictors of cardiovascular risk and their independent association with stroke and mortality outcomes in AF has consistently been demonstrated.[5](#jah33798-bib-0005){ref-type="ref"}, [6](#jah33798-bib-0006){ref-type="ref"}, [7](#jah33798-bib-0007){ref-type="ref"}, [8](#jah33798-bib-0008){ref-type="ref"}, [9](#jah33798-bib-0009){ref-type="ref"} Several factors influence the concentrations of cardiac biomarkers, including the presence of LVH.[10](#jah33798-bib-0010){ref-type="ref"}, [11](#jah33798-bib-0011){ref-type="ref"}, [12](#jah33798-bib-0012){ref-type="ref"}, [13](#jah33798-bib-0013){ref-type="ref"} To date, there are limited data on the association of cardiac biomarkers with LVH in patients with AF, neither on the combination of these 2 indicators, to further increase the understanding of and improve the risk stratification in AF.

In the present RE‐LY (Randomized Evaluation of Long‐Term Anticoagulation Therapy)[14](#jah33798-bib-0014){ref-type="ref"} trial, we investigated the relationship between cardiovascular biomarkers (NT‐proBNP \[N‐terminal pro‐B‐type natriuretic peptide\], high‐sensitivity cardiac troponin I \[hs‐cTnI\] and T \[hs‐cTnT\], and growth differentiation factor‐15 \[GDF‐15\]) and LVH diagnosed by ECG and their individual independent associations with outcomes in 5275 anticoagulated patients with AF using baseline plasma samples.

Methods {#jah33798-sec-0010}
=======

The data and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Study Population and Trial Design {#jah33798-sec-0011}
---------------------------------

The study organization, trial design, patient characteristics, and outcomes of the RE‐LY trial have been published previously.[14](#jah33798-bib-0014){ref-type="ref"}, [15](#jah33798-bib-0015){ref-type="ref"} Patients were recruited from 967 centers in 44 countries between November 2005 and December 2007. A total of 18 113 patients with AF, with at least 1 additional risk factor for stroke, were randomized in a 1:1:1 manner to receive either fixed doses of dabigatran (110 or 150 mg twice daily) in a blinded manner or adjusted‐dose warfarin (target international normalized ratio, 2.0--3.0) in an unblinded manner for a median of 2 years.[15](#jah33798-bib-0015){ref-type="ref"} All patients were centrally randomized through an interactive voice response system located at the Coordinating Centre at Population Health Research Institute (Hamilton, Ontario, Canada). Estimated glomerular filtration rate \<30 mL/min, according to Cockcroft‐Gault, was an exclusion criterion. The primary efficacy outcome was fatal and nonfatal stroke (ischemic, hemorrhagic, or unspecified) or systemic embolism. The main safety outcome was major bleeding, defined as (1) a reduction in hemoglobin level of at least 20 g/L, (2) transfusion of at least 2 units of blood, or (3) symptomatic bleeding in a critical area or organ. Approval by the appropriate ethics committees was obtained at all sites. All patients provided written informed consent.

Of the 18 113 patients included in the RE‐LY trial, LVH data by ECG were available in 10 372. Of these, 5275 patients also had baseline measurements available for at least 1 of the cardiovascular biomarkers (NT‐proBNP, hs‐cTnI, hs‐cTnT, and GDF‐15). The data set for this study was accordingly 5275 patients. A flowchart is presented in Figure [S1](#jah33798-sup-0001){ref-type="supplementary-material"}.

ECG Procedure and LVH Definition {#jah33798-sec-0012}
--------------------------------

The ECG procedure has been described in detail previously.[4](#jah33798-bib-0004){ref-type="ref"} Briefly, a 25‐mm/s 12‐lead ECG obtained at study entry was examined by an expert reader (G.M.), blinded to the patients' features and randomized treatment. Electrographic LVH was defined according to the Cornell voltage criteria (R wave in aVL+S wave in V3 \>2.0 mV in women or \>2.4 mV in men) or by presence of strain pattern (ST‐segment depression of at least 0.5 mm and inverted T wave in at least 1 of the leads in I, II, aVL, or V4 to V6). LVH diagnosis by electrocardiography was thus a binary variable (yes/no). This definition of electrographic LVH is considered simple and applicable in large populations and has been validated in large studies.[4](#jah33798-bib-0004){ref-type="ref"}, [16](#jah33798-bib-0016){ref-type="ref"}, [17](#jah33798-bib-0017){ref-type="ref"} In a large validation study in hypertensive patients, this definition yielded 34% sensitivity and 91% specificity with echocardiographic LVH as reference, performed better than traditional ECG criteria of LVH, and identified subjects at higher risk of cardiovascular outcomes.[17](#jah33798-bib-0017){ref-type="ref"}

Laboratory Methods {#jah33798-sec-0013}
------------------

Venous blood was drawn at randomization, before initiation of study treatment, using a 21/22‐gauge needle into vacutainer tubes containing EDTA. The blood was centrifuged within 30 minutes at 2000*g* for 10 minutes. The tubes were thereafter immediately frozen at −20°C or colder. Aliquots were stored at −70°C to allow for central batch analysis.

Plasma concentration of GDF‐15 was determined by Elecsys GDF‐15 precommercial assay kit P03 with the same standardization as the recently introduced routine reagent (Roche Diagnostics).[9](#jah33798-bib-0009){ref-type="ref"}, [18](#jah33798-bib-0018){ref-type="ref"} cTnI concentrations were measured on Architect i1000SR (Abbott Diagnostics) using hs assays. cTnT and NT‐proBNP were analyzed with high‐sensitivity assays on Cobas Analytics e601 and c501 Immunoanalyzer (Roche Diagnostics). These biochemical analyses were performed centrally at Uppsala Clinical Research Center laboratory (Uppsala, Sweden), according to the instructions of the manufacturer. Details about the characteristics of these assays have been reported previously.[19](#jah33798-bib-0019){ref-type="ref"}, [20](#jah33798-bib-0020){ref-type="ref"}

Statistical Analyses {#jah33798-sec-0014}
--------------------

The numbers of patients with available GDF‐15, NT‐proBNP, hs‐cTnI, and hs‐cTnT were 4850, 5239, 4948, and 4892, respectively. There were relatively few missing data (\<1%) on other covariates, and a complete case analysis was therefore implemented. In a univariate analysis comparing baseline characteristics of patients between categories of LVH, continuous variables were reported with median and first and third quartiles and compared by Wilcoxon rank sum test. Categorical variables were reported as number and column percentage and compared by χ^2^ tests.

Continuous biomarker levels were log transformed and used as outcome in linear regression models, including LVH category (no/yes), age, sex, body mass index, current smoking, heart failure, hypertension, prior myocardial infarction, diabetes mellitus, systolic blood pressure, permanent AF, creatinine clearance, digoxin use, and angiotensin‐converting enzyme inhibitors/angiotensin II receptor blocker as explanatory variables, on the basis of clinical importance. The results are presented as model adjusted geometric mean ratios of biomarker levels between LVH categories, with nominal CIs and *P* values. Observed marginal distributions were used in the model adjustment.

The impact of biomarkers at baseline on the association between LVH and outcomes was analyzed by adding biomarkers (continuous, log‐transformed values) to Cox regression models, including LVH category, randomized treatment, CHA~2~DS~2~‐VASc score, permanent AF at entry, smoking, digoxin use, and creatinine clearance. Biomarkers were added individually to the model, as well as simultaneously in prespecified combinations. The interactions between LVH category and biomarkers were analyzed by Cox regression models, including LVH category, biomarker, and interaction between LVH category and biomarker. The biomarkers were included as continuous, log transformed, and fitted using restricted cubic splines with 4 knots, located at the 5th, 35th, 65th, and 95th percentiles. Plots of estimated probability of event at 1 year against biomarker values for each LVH category were constructed. The *P* values for the tests of interactions are reported.

The impact of LVH on the association between biomarkers and outcomes was analyzed by adding LVH to Cox regression models, including 1 biomarker (continuous, log transformed) and randomized treatment, CHA~2~DS~2~‐VASc score, permanent AF at entry, smoking, digoxin use, and creatinine clearance.

All statistical tests were 2 tailed and performed at the 0.05 significance level. Because the analyses were exploratory, no adjustments for multiple comparisons were made. The proportional hazards assumption was evaluated by plotting Schoenfeld residuals against rank time and fitting a smooth curve. All statistical analyses were performed using SAS software, version 9.4 (SAS Institute Inc, Cary, NC).

Results {#jah33798-sec-0015}
=======

Baseline Data and Clinical Characteristics According to Presence of LVH {#jah33798-sec-0016}
-----------------------------------------------------------------------

The median age was 72.0 years, and 3431 patients (65%) were men. LVH was present in 1257 patients (23.8%). Baseline characteristics and comorbidities according to presence of LVH are shown in Table [1](#jah33798-tbl-0001){ref-type="table"}.

###### 

Demographics and Clinical Characteristics According to LVH Category

  Baseline Data                                                      No LVH (N=4018)        LVH (N=1257)           *P* Value[a](#jah33798-note-0003){ref-type="fn"}
  ------------------------------------------------------------------ ---------------------- ---------------------- --------------------------------------------------
  Age, median (quartile 1--quartile 3), y                            72.0 (67.0--77.0)      72.0 (66.0--78.0)      0.74
  Age ≥75 y, n (%)                                                   1531 (38.1)            503 (40.0)             0.22
  Male sex, n (%)                                                    2683 (66.8)            748 (59.5)             \<0.0001
  Current smoker, n (%)                                              303 (7.5)              107 (8.5)              0.26
  Weight, median (quartile 1--quartile 3), kg                        82.0 (71.0--95.0)      78.0 (67.0--90.0)      \<0.0001
  Body mass index, median (quartile 1--quartile 3), kg/m^2^          28.3 (25.3--32.0)      27.6 (24.8--31.0)      \<0.0001
  Systolic blood pressure, median (quartile 1--quartile 3), mm Hg    130.0 (120.0--140.0)   132.0 (120.0--145.0)   \<0.0001
  Diastolic blood pressure, median (quartile 1--quartile 3), mm Hg   80.0 (70.0--85.0)      80.0 (70.0--86.0)      0.75
  Heart rate, median (quartile 1--quartile 3), bpm                   76.0 (68.0--86.0)      76.0 (66.0--87.0)      0.94
  Type of atrial fibrillation, n (%)                                                                               
  Paroxysmal                                                         632 (15.7)             154 (12.3)             0.005
  Persistent                                                         1285 (32.0)            397 (31.6)             
  Permanent                                                          2099 (52.3)            706 (56.2)             
  Heart failure, n (%)                                               1348 (33.5)            651 (51.8)             \<0.0001
  Diabetes mellitus, n (%)                                           837 (20.8)             329 (26.2)             \<0.0001
  Coronary artery disease, n (%)                                     896 (22.3)             319 (25.4)             0.0237
  Hypertension, n (%)                                                3105 (77.3)            1010 (80.4)            0.0217
  Vascular disease, n (%)[b](#jah33798-note-0004){ref-type="fn"}     669 (16.7)             266 (21.2)             0.0003
  History of stroke/SEE/TIA, n (%)                                   872 (21.7)             279 (22.2)             0.71
  VKA use class at study entry, n (%)                                                                              
  Naive                                                              1869 (46.5)            625 (49.7)             0.0469
  Statin at baseline, n (%)                                          1649 (41.0)            474 (37.7)             0.0355
  ARB and/or ACEi at baseline, n (%)                                 2598 (64.7)            938 (74.6)             \<0.0001
  β Blocker at baseline, n (%)                                       2558 (63.7)            809 (64.4)             0.65
  Digoxin at baseline, n (%)                                         1209 (30.1)            638 (50.8)             \<0.0001
  CrCL at baseline, median (quartile 1--quartile 3), mL/min          70.4 (55.6--88.6)      64.3 (50.0--81.1)      \<0.0001
  CrCL class at baseline, n (%)                                                                                    
  \<50 mL/min                                                        639 (16.1)             312 (25.1)             \<0.0001
  50--\<80 mL/min                                                    1929 (48.5)            601 (48.3)             
  ≥80 mL/min                                                         1412 (35.5)            332 (26.7)             
  Left ventricular ejection fraction, n (%)                                                                        
  ≤40%                                                               343 (8.5)              232 (18.5)             NA[c](#jah33798-note-0005){ref-type="fn"}
  \>40%                                                              1493 (37.2)            424 (33.7)             
  Unknown                                                            2182 (54.3)            501 (47.8)             
  CHA~2~DS~2~VASc score, median (quartile 1--quartile 3)             3.0 (2.0--4.0)         4.0 (3.0--5.0)         \<0.0001
  CHA~2~DS~2~VASc score category, n (%)                                                                            
  ≤2                                                                 1051 (25.3)            239 (19.0)             \<0.0001
  \>2                                                                3003 (74.7)            1018 (81.0)            
  NT‐proBNP                                                                                                        
  Median (quartile 1--quartile 3), ng/L                              931 (575--1453)        1354 (775--2277)       \<0.0001
  n                                                                  1250                   3989                   
  Troponin I                                                                                                       
  Median (quartile 1--quartile 3), ng/L                              6.0 (4.0--10.0)        12.0 (6.6--21.0)       \<0.0001
  n                                                                  1191                   3793                   
  Troponin T                                                                                                       
  Median (quartile 1--quartile 3), ng/L                              11.2 (7.4--17.2)       17.1 (10.8--27.1)      \<0.0001
  n                                                                  1167                   3725                   
  GDF‐15                                                                                                           
  Median (quartile 1--quartile 3), ng/L                              1472 (1103--2090)      1785 (1271--2601)      \<0.0001
  n                                                                  1159                   3691                   

ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; bpm, beats per minute; CrCL, creatinine clearance; GDF‐15, growth differentiation factor‐15; LVH, left ventricular hypertrophy; NA, not applicable; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; SEE, systemic embolism; TIA, transient ischemic attack; VKA, vitamin K antagonist.

The *P* value is for the comparison between groups and is based on the χ^2^ test for categorical variables and the Kruskal‐Wallis test for continuous variables.

Vascular disease: peripheral artery disease or prior myocardial infarction.

Not calculated because of a large proportion with unknown values.

All the cardiovascular biomarkers and several clinical characteristics were significantly associated with presence of LVH. Patients with AF and LVH more often had heart failure, poor renal function, diabetes mellitus, hypertension, permanent AF, and vascular disease. They had also more commonly been prescribed digoxin, angiotensin‐converting enzyme inhibitors, and angiotensin II receptor blocker treatment, but less commonly statins. A slightly larger proportion of patients with both AF and LVH were naïve to oral anticoagulation therapy. In linear regression analyses adjusting for baseline characteristics, LVH was significantly (*P*\<0.0001) associated with higher levels of all analyzed biomarkers (Table [2](#jah33798-tbl-0002){ref-type="table"}).

###### 

Linear Regression Analysis of Biomarker Level According to LVH Category

  Biomarker          Without LVH         With LVH            Ratio               *P* Value
  ------------------ ------------------- ------------------- ------------------- -----------
  NT‐proBNP, ng/L    924 (903--946)      1220 (1169--1273)   1.32 (1.26--1.39)   \<0.0001
  Troponin I, ng/L   7.1 (6.9--7.3)      11.8 (11.2--12.5)   1.67 (1.57--1.78)   \<0.0001
  Troponin T, ng/L   11.6 (11.4--11.9)   16.2 (15.6--16.9)   1.40 (1.34--1.46)   \<0.0001
  GDF‐15, ng/L       1589 (1567--1612)   1735 (1690--1780)   1.09 (1.06--1.12)   \<0.0001

Data are given as geometric mean (95% CI). Multiple linear regression analyses with log‐transformed continuous biomarker levels as outcome in models including LVH category (no/yes), age, sex, body mass index, current smoking, heart failure, hypertension, prior myocardial infarction, diabetes mellitus, systolic blood pressure, permanent atrial fibrillation, creatinine clearance, digoxin use, and angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker as explanatory variables. GDF‐15 indicates growth differentiation factor‐15; LVH, left ventricular hypertrophy; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.

The baseline characteristics of the present cohort with available data on both biomarkers and LVH were similar to the larger cohort with available LVH data (Table [S1](#jah33798-sup-0001){ref-type="supplementary-material"}).

Prognostic Value of LVH and Cardiac Biomarker Levels {#jah33798-sec-0017}
----------------------------------------------------

During a median follow‐up of 2.0 years, 165 patients developed a stroke, 370 died, and 258 had a major bleeding event. For stroke, the hazard ratios (95% CIs) per 50% increase after adjustment for clinical risk factors and LVH were as follows: NT‐proBNP, 1.09 (1.00--1.19); hs‐cTnI, 1.09 (1.03--1.15); hs‐cTnT, 1.14 (1.06--1.24); and GDF‐15, 1.22 (1.08--1.38) (all *P*\<0.05) (Figure [1](#jah33798-fig-0001){ref-type="fig"}). For death, the hazard ratios (95% CIs) per 50% increase were as follows: NT‐proBNP, 1.24 (1.17--1.31); hs‐cTnI, 1.13 (1.10--1.17); hs‐cTnT, 1.28 (1.23--1.34); and GDF‐15, 1.31 (1.22--1.42) (all *P*\<0.0001) (Figure [1](#jah33798-fig-0001){ref-type="fig"}). Elevated biomarker levels were consistently associated with poorer prognosis in patients with AF, regardless of LVH (Figure [2](#jah33798-fig-0002){ref-type="fig"}). Results were similar for the association between biomarker levels and major bleeding (Figure [1](#jah33798-fig-0001){ref-type="fig"}).

![Impact of left ventricular hypertrophy (LVH) on the association between baseline biomarkers and stroke or systemic embolism (SEE), all‐cause mortality, and major bleeding outcomes. GDF‐15 indicates growth differentiation factor‐15; HR, hazard ratio; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.](JAH3-8-e010107-g001){#jah33798-fig-0001}

![One‐year risk for all‐cause mortality by left ventricular hypertrophy (LVH) category according to levels of NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide; **A**), troponin I (**B**), troponin T (**C**), and growth differentiation factor‐15 (GDF‐15; **D**). The biomarkers were included as continuous, log transformed, and fitted using restricted cubic splines with 4 knots, located at the 5th, 35th, 65th, and 95th percentiles.](JAH3-8-e010107-g002){#jah33798-fig-0002}

The influence of baseline biomarker levels on the association between LVH and outcomes was analyzed by adding biomarkers (continuous, log transformed) to Cox regression models adjusted for several baseline characteristics (Table [3](#jah33798-tbl-0003){ref-type="table"}).

###### 

Association Between LVH and Outcomes According to Adjustment for Biomarkers

  Outcome                       Biomarker Added in Model          Events, %/Year   Adjusted Cox Model                       
  ----------------------------- --------------------------------- ---------------- -------------------- ------------------- --------
  Stroke or systemic embolism   LVH without biomarkers in model   105 (1.46)       43 (1.94)            1.14 (0.79--1.64)   0.49
  Troponin I                    1.02 (0.70--1.50)                 0.91                                                      
  Troponin T                    1.03 (0.71--1.49)                 0.89                                                      
  NT‐proBNP                     1.06 (0.73--1.54)                 0.75                                                      
  GDF‐15                        1.10 (0.77--1.59)                 0.60                                                      
  Troponin T+NT‐proBNP          0.99 (0.68--1.44)                 0.95                                                      
  Troponin T+NT‐proBNP+GDF‐15   1.00 (0.69--1.46)                 0.99                                                      
  All‐cause mortality           LVH without biomarkers in model   204 (2.83)       119 (5.38)           1.60 (1.27--2.02)   0.0001
  Troponin I                    1.33 (1.04--1.70)                 0.0249                                                    
  Troponin T                    1.28 (1.01--1.63)                 0.0408                                                    
  NT‐proBNP                     1.35 (1.07--1.72)                 0.0143                                                    
  GDF‐15                        1.53 (1.21--1.93)                 0.0005                                                    
  Troponin T+NT‐proBNP          1.17 (0.92--1.49)                 0.21                                                      
  Troponin T+NT‐proBNP+GDF‐15   1.19 (0.93--1.51)                 0.16                                                      
  Major bleed                   LVH without biomarkers in model   155 (2.15)       67 (3.03)            1.27 (0.95--1.70)   0.12
  Troponin I                    1.20 (0.88--1.63)                 0.25                                                      
  Troponin T                    1.12 (0.83--1.51)                 0.47                                                      
  NT‐proBNP                     1.24 (0.92--1.68)                 0.16                                                      
  GDF‐15                        1.22 (0.91--1.64)                 0.19                                                      
  Troponin T+NT‐proBNP          1.12 (0.83--1.51)                 0.47                                                      
  Troponin T+NT‐proBNP+GDF‐15   1.18 (0.87--1.59)                 0.30                                                      

Biomarkers included as continuous, log‐transformed, variables. Patients with no missing data for clinical risk factors, troponin T, GDF‐15, and NT‐proBNP were included in the analysis. GDF‐15 indicates growth differentiation factor‐15; HR, hazard ratio; LVH, left ventricular hypertrophy; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.

*P* value for effect of LVH.

LVH did not remain significantly associated with stroke or death after adjustment for biomarker levels. Similarly, there was no improvement in C‐indexes for stroke/systemic embolism, all‐cause mortality, or major bleeding events by adding LVH data to risk models containing the cardiovascular biomarkers (Table [S2](#jah33798-sup-0001){ref-type="supplementary-material"}). The biomarkers, however, provided significant improvements when added on top of models containing LVH data.

Discussion {#jah33798-sec-0018}
==========

The present study provides new insight into the association between the cardiovascular biomarkers NT‐proBNP, troponin, and GDF‐15 and LVH in patients with AF. There was an independent association between LVH and increased levels of each biomarker in multiple linear regression analyses, in particular for the cardiac biomarkers (NT‐proBNP and troponin). Overall, the biomarkers remained independently associated with cardiovascular outcomes after adjustment for information on LVH status. On the other hand, LVH did not remain an independent predictor for stroke or mortality after adjustment for the cardiac biomarkers NT‐proBNP and troponin. Accordingly, in patients with AF, cardiac biomarkers were able to further identify patients with lower or higher risk both in the presence and in the absence of LVH by ECG.

LVH is a strong marker for adverse outcomes in several populations ranging from the general population to those with cardiovascular diseases,[3](#jah33798-bib-0003){ref-type="ref"}, [17](#jah33798-bib-0017){ref-type="ref"}, [21](#jah33798-bib-0021){ref-type="ref"}, [22](#jah33798-bib-0022){ref-type="ref"} but is not included among the traditional risk factors for stroke or death in AF.[1](#jah33798-bib-0001){ref-type="ref"}, [2](#jah33798-bib-0002){ref-type="ref"} LVH according to either ECG or echocardiography was recently shown to be a marker of increased risk for adverse outcomes also in patients with AF.[4](#jah33798-bib-0004){ref-type="ref"}, [23](#jah33798-bib-0023){ref-type="ref"} Similarly, the cardiovascular biomarkers NT‐proBNP,[5](#jah33798-bib-0005){ref-type="ref"}, [8](#jah33798-bib-0008){ref-type="ref"}, [24](#jah33798-bib-0024){ref-type="ref"}, [25](#jah33798-bib-0025){ref-type="ref"}, [26](#jah33798-bib-0026){ref-type="ref"} troponin,[6](#jah33798-bib-0006){ref-type="ref"}, [7](#jah33798-bib-0007){ref-type="ref"}, [11](#jah33798-bib-0011){ref-type="ref"}, [27](#jah33798-bib-0027){ref-type="ref"}, [28](#jah33798-bib-0028){ref-type="ref"} and GDF‐15[9](#jah33798-bib-0009){ref-type="ref"}, [29](#jah33798-bib-0029){ref-type="ref"}, [30](#jah33798-bib-0030){ref-type="ref"}, [31](#jah33798-bib-0031){ref-type="ref"} are powerful risk markers for cardiovascular outcomes in both the general population and in patients with cardiovascular diseases, including AF.[32](#jah33798-bib-0032){ref-type="ref"} In the present study, we confirmed the significant independent associations between the levels of these cardiovascular biomarkers and adverse outcomes in patients with AF, even after adjustment for LVH by ECG. Biomarkers thus remained significant predictors for cardiovascular outcomes both in the presence as well as in the absence of LVH. In contrast, the association between LVH and outcomes did not remain after adjustment for biomarker levels. Previous studies on the prognostic impact of these biomarkers in other cohorts have accounted for the presence of LVH to a varying degree. This issue was recently investigated comprehensively in a general population in the DHS (Dallas Heart Study) cohort, which confirmed the prognostic value of the cardiac biomarkers.[13](#jah33798-bib-0013){ref-type="ref"} In the present study, we extended these observations and showed a prognostic value of the levels of the cardiovascular biomarkers beyond information on LVH also in patients with AF.

Causes of LVH mainly include hemodynamic states with increased afterload, such as hypertension and aortic valvular disease, besides specific genetic myocardial diseases, such as hypertrophic cardiomyopathies.[33](#jah33798-bib-0033){ref-type="ref"}, [34](#jah33798-bib-0034){ref-type="ref"} In addition, the levels of troponin, natriuretic peptides, and GDF‐15 have been shown to increase with progression of LVH.[11](#jah33798-bib-0011){ref-type="ref"}, [12](#jah33798-bib-0012){ref-type="ref"}, [13](#jah33798-bib-0013){ref-type="ref"}, [35](#jah33798-bib-0035){ref-type="ref"} LVH and elevated levels of cardiac biomarkers thus seem to have several causes in common. On the other hand, biomarker levels not only reflect *structural* abnormalities in the heart, but are also related to cardiac and vascular function.[11](#jah33798-bib-0011){ref-type="ref"}, [12](#jah33798-bib-0012){ref-type="ref"}, [36](#jah33798-bib-0036){ref-type="ref"} Besides the positive interaction between these variables, the reasons that cardiovascular biomarkers are stronger risk markers than LVH may be because of the fact that they also indicate underlying potentially clinically silent cardiovascular disease processes or dysfunctions that are also related to cardiovascular outcomes.[7](#jah33798-bib-0007){ref-type="ref"}, [8](#jah33798-bib-0008){ref-type="ref"}, [9](#jah33798-bib-0009){ref-type="ref"}, [37](#jah33798-bib-0037){ref-type="ref"} For example, the levels of cardiac biomarkers seem to signal adverse remodeling in patients with LVH, indicating a transition from structural LVH to clinical heart failure.[13](#jah33798-bib-0013){ref-type="ref"} This transition was recently termed "malignant LVH" and confers a state of even poorer prognosis.[38](#jah33798-bib-0038){ref-type="ref"} There are thus several reasons that cardiovascular biomarkers provide additional dimensions of information on risk of cardiovascular events that also seem to include the signal provided by LVH in patients with AF. This notion is also supported in the current findings, which show no added prognostic value of LVH by ECG in predictive models already containing the plasma biomarkers.

In the clinical setting, ECG recording is fundamental in the management of patients with AF to obtain information on heart rhythm and heart rate.[1](#jah33798-bib-0001){ref-type="ref"}, [2](#jah33798-bib-0002){ref-type="ref"} It therefore provides easy accessible screening of other possible abnormalities, such as LVH, and may aid in the decision about rate or rhythm control strategies and/or the selection of antiarrhythmic drugs.[1](#jah33798-bib-0001){ref-type="ref"}, [2](#jah33798-bib-0002){ref-type="ref"}, [39](#jah33798-bib-0039){ref-type="ref"} For risk stratification, electrographic LVH data may still provide practical prognostic information for cardiovascular events in AF. However, if plasma biomarker measurements are available, they can improve risk prediction in patients with AF both in the presence or absence of LVH.[4](#jah33798-bib-0004){ref-type="ref"}, [40](#jah33798-bib-0040){ref-type="ref"}, [41](#jah33798-bib-0041){ref-type="ref"} Measurement of the cardiac biomarkers NT‐proBNP and troponin would thus probably be useful as part of the routine evaluation of a patient with AF.

Limitations {#jah33798-sec-0019}
-----------

The present study was a post hoc analysis based on a subgroup of participants in the RE‐LY trial with ECGs suitable for LVH analysis and biomarker measurements at baseline available. Generalizability of our results may thus be limited. Although baseline characteristics in patients with available biomarker measurements were almost identical to the total cohort with available LVH data, the annual event rate was somewhat lower in those with available biomarker measurements. This may have influenced the results on the association of LVH with outcomes in presence of biomarkers.[4](#jah33798-bib-0004){ref-type="ref"} LVH was assessed by ECG and not magnetic resonance imaging or echocardiography. ECG assessment of LVH traditionally indicates the presence or absence of LVH, not the actual severity. However, a validated definition for electrographic LVH was applied in the analysis, which also encompassed ECG strain patterns in addition to traditional voltage criteria, thereby providing additional prognostic information because strain pattern is associated with higher left ventricular mass indexes.[21](#jah33798-bib-0021){ref-type="ref"} Moreover, ECG screening is often used in large‐scale screening programs for practical reasons.

Conclusions {#jah33798-sec-0020}
===========

Levels of cardiac biomarkers are significantly associated with LVH. The prognostic value of biomarkers on stroke, death, and major bleeding is not affected by LVH. The association of LVH with outcomes is attenuated in the presence of cardiac biomarkers.

Sources of Funding {#jah33798-sec-0021}
==================

The RE‐LY (Randomized Evaluation of Long‐Term Anticoagulation Therapy) trial was funded by Boehringer Ingelheim Pharmaceuticals.

Disclosures {#jah33798-sec-0022}
===========

Dr Hijazi reports receiving lecture fees from Boehringer Ingelheim, Bristol‐Myers Squibb (BMS), and Pfizer; consulting fees from Merck Sharp & Dohme and BMS/Pfizer; and institutional research grants from Boehringer Ingelheim, BMS, and Pfizer. Dr Verdecchia reports research grants, consulting fees, and lecture fees from Boehringer Ingelheim. Dr Oldgren reports consulting and lecture fees from Boehringer‐Ingelheim, Bayer, BMS, and Pfizer. Ms Andersson reports an institutional research grant from BMS/Pfizer. Dr Di Pasquale reports research grants, consulting fees, and lecture fees from Boehringer Ingelheim. Dr Connolly reports consulting and research grants from Boehringer Ingelheim. Dr Ezekowitz is a consultant for and/or has received consulting/honoraria fees from Boehringer Ingelheim, Pfizer, Sanofi, BMS, Portola, Bayer, Daiichi‐Sankyo, Medtronic, Aegerion, Merck, Johnson & Johnson, Gilead, Janssen Scientific Affairs, Pozen Inc, Amgen, Coherex, and Armetheon. Dr Yusuf reports research grants from Boehringer Ingelheim. Dr Wallentin reports institutional research grants, consultancy and lecture fees, and travel support from AstraZeneca, BMS, Pfizer, Boehringer Ingelheim, and GlaxoSmithKline; honoraria from GlaxoSmithKline; institutional research grant from Merck & Co and Roche; consultancy fees from Abbot; and holds 2 patents involving growth differentiation factor‐15. The remaining authors have no disclosures to report.

Supporting information
======================

###### 

**Figure S1.** Flowchart.

**Table S1.** Demographics and Clinical Characteristics for the Present Subgroup With Biomarkers and LVH‐Data Available in Comparison to the Cohort With LVH‐Data Available

**Table S2.** Discriminative Ability of Models With and Without Biomarkers and/or Left Ventricular Hypertrophy

###### 

Click here for additional data file.
